CLINICAL TRIALS PROFILE FOR RENFLEXIS
✉ Email this page to a colleague
All Clinical Trials for RENFLEXIS
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04305145 ↗ | Infliximab for Treatment of Ipilimumab Colitis | Recruiting | Massachusetts General Hospital | Phase 2 | 2020-08-31 | This research study is evaluating the effectiveness and safety of infliximab therapy compared with steroids in the treatment of ipilimumab-induced colitis in patients with III/IV melanoma. |
NCT05034536 ↗ | Pembrolizumab + Infliximab for Metastatic Melanoma | Not yet recruiting | Massachusetts Institute of Technology | Phase 2 | 2022-01-01 | The purpose of this research is to test the safety and effectiveness of the investigational combination of pembrolizumab and infliximab in treating metastatic melanoma. |
NCT05034536 ↗ | Pembrolizumab + Infliximab for Metastatic Melanoma | Not yet recruiting | Massachusetts General Hospital | Phase 2 | 2022-01-01 | The purpose of this research is to test the safety and effectiveness of the investigational combination of pembrolizumab and infliximab in treating metastatic melanoma. |
NCT05660746 ↗ | Precise Infliximab Exposure and Pharmacodynamic Control | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2/Phase 3 | 2023-02-01 | Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best possible response to infliximab compared to standard dosing (conventional dosing). |
NCT05660746 ↗ | Precise Infliximab Exposure and Pharmacodynamic Control | Not yet recruiting | Children's Hospital Medical Center, Cincinnati | Phase 2/Phase 3 | 2023-02-01 | Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best possible response to infliximab compared to standard dosing (conventional dosing). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RENFLEXIS
Condition Name
Clinical Trial Locations for RENFLEXIS
Trials by Country
Clinical Trial Progress for RENFLEXIS
Clinical Trial Phase
Clinical Trial Sponsors for RENFLEXIS
Sponsor Name